OM1’s Dr. Richard Gliklich presents on leveraging the AAO-HFN Reg-ent Registry for research at the FDA-MDEpiNet conference “Cochlear Implant Innovation, Research and Advancement (CIRCA). View Agenda >>
Taylor & Francis Online Published: January 20, 2022 Read the Full Manuscript >> Objective To compare healthcare resource use (HCRU) in patients undergoing sinus surgery with or without steroid-eluting sinus implants. Methods A retrospective, observational cohort study using real-world evidence data (OM1, Inc, Boston, MA, USA) was conducted on adult patients with chronic rhinosinusitis (CRS)[…]
December 20, 2021 – Orphanet Journal of Rare Diseases Read the Full Article >> Background Fabry disease (FD) is a rare genetic disorder characterized by glycosphingolipid accumulation and progressive damage across multiple organ systems. Due to its heterogeneous presentation, the condition is likely significantly underdiagnosed. Several approaches, including provider education efforts and newborn screening, have[…]
SEPTEMBER 15, 2021 By Joseph Zabinski, PhD, Senior Director of AI & Precision Medicine, OM1 As innovation in devices and diagnostics accelerates, research approaches and outcomes programs also need to advance to support these developments with high-quality evidence. At the same time, demonstrating the effectiveness of a device can be challenging because outcomes depend highly[…]
BOSTON, July 16, 2021 /PRNewswire/ — OM1, a health technology company focused on real-world outcomes for chronic conditions, today announced an $85 million financing led by D1 Capital Partners, Kaiser Permanente, and Breyer Capital, with participation from existing investors, including General Catalyst (GC), Polaris Partners, Scale Venture Partners, 7wire Ventures, and Glikvest. OM1 partners with providers, medical societies, payers, and[…]
